June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
The efficacy of intravitreal ranibizumab for the treatment of macular oedema secondary to retinal vein occlusions in a treatment-naïve cohort: 6-month outcomes
Author Affiliations & Notes
  • Masara Laginaf
    Ophthalmology, Frimley Health NHS Foundation Trust, Frimley, United Kingdom
  • Adam Lewis
    Ophthalmology, Frimley Health NHS Foundation Trust, Frimley, United Kingdom
  • Manju Chandran
    Ophthalmology, Frimley Health NHS Foundation Trust, Frimley, United Kingdom
  • Geeta Menon
    Ophthalmology, Frimley Health NHS Foundation Trust, Frimley, United Kingdom
  • Footnotes
    Commercial Relationships Masara Laginaf, None; Adam Lewis, None; Manju Chandran, None; Geeta Menon, Alcon (F), Allergan (F), Bayer (F), Novartis (F)
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 204. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Masara Laginaf, Adam Lewis, Manju Chandran, Geeta Menon; The efficacy of intravitreal ranibizumab for the treatment of macular oedema secondary to retinal vein occlusions in a treatment-naïve cohort: 6-month outcomes. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):204. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: Ranibizumab has been shown to significantly improve visual and anatomical outcomes in patients with macular oedema due to branch and central retinal vein occlusions (RVOs) in the BRAVO and CRUISE studies respectively. We performed a retrospective case series to determine the efficacy of ranibizumab for treatment-naïve macular oedema secondary to branch, central and hemi RVOs within a foundation trust hospital setting in England, United Kingdom.

Methods: We isolated 29 treatment-naïve patients receiving ranibizumab (0.5mg) for RVO-related macular oedema (18 branch, 10 central and 1 hemi-RVO). All patients received initial monthly injections, which were continued until the visual acuity (VA) remained stable for 3 consecutive monthly assessments. Retreatment criteria was based on stability of VA and the presence of intraretinal fluid (IRF). The primary outcomes measured were best corrected visual acuity (BCVA), using Early Treatment in Diabetic Retinopathy Study (ETDRS) acuity testing, and central macular thickness (CMT), evaluated with optical coherence tomography (OCT). Statistical analysis was carried out using the paired t test.

Results: There was a statistically significant gain in BCVA from baseline to month 1 of 11.65 letters (p=<0.0001, n=29). The CMT was significantly reduced by 216.03μm from baseline to month 1 (p=<0.0001, n=29). At 6 months, a significant gain in BCVA of 10.13 letters (p=0.0015, n= 23), and a significant reduction in CMT of 248.52μm (p=<0.0001, n=23) was maintained. 26.10% of patients gained ≥15 letters at 6 months. The mean number of injections received was 4. There were no ocular or systemic adverse effects reported during the follow-up period.

Conclusions: Ranibizumab, alone, is a safe and effective treatment for patients with visual impairment due to macular oedema secondary to RVO. Statistically significant improvements in BCVA and CMT were maintained over a 6-month follow-up period.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×